Iovance Biotherapeutics, Inc. 2LB.F Stock
Iovance Biotherapeutics, Inc. Price Chart
Iovance Biotherapeutics, Inc. 2LB.F Financial and Trading Overview
| Iovance Biotherapeutics, Inc. stock price | 12.23 EUR |
| Previous Close | 5.73 EUR |
| Open | 5.91 EUR |
| Bid | 6.66 EUR x 100000 |
| Ask | 6.72 EUR x 100000 |
| Day's Range | 5.91 - 5.91 EUR |
| 52 Week Range | 3.11 - 8.79 EUR |
| Volume | 507 EUR |
| Avg. Volume | 42 EUR |
| Market Cap | 1.53B EUR |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.31 EUR |
2LB.F Valuation Measures
| Enterprise Value | 1.19B EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.624889 |
| PEG Ratio (5 yr expected) | 0.61 |
| Price/Sales (ttm) | 2165.4387 |
| Price/Book (mrq) | 2.2413664 |
| Enterprise Value/Revenue | 1676.139 |
| Enterprise Value/EBITDA | -2.727 |
Trading Information
Iovance Biotherapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.36 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 8.79 EUR |
| 52 Week Low | 3.11 EUR |
| 50-Day Moving Average | 4.25 EUR |
| 200-Day Moving Average | 5.73 EUR |
2LB.F Share Statistics
| Avg. Volume (3 month) | 42 EUR |
| Avg. Daily Volume (10-Days) | 150 EUR |
| Shares Outstanding | 255.92M |
| Float | 212M |
| Short Ratio | N/A |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 95.65% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -25236.88% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.90% |
| Return on Equity (ttm) | -81.10% |
Income Statement
| Revenue (ttm) | 707K EUR |
| Revenue Per Share (ttm) | 0.003 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -434616992 EUR |
| Net Income Avi to Common (ttm) | -432976992 EUR |
| Diluted EPS (ttm) | -1.93 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 361.37M EUR |
| Total Cash Per Share (mrq) | 1.41 EUR |
| Total Debt (mrq) | 79.48M EUR |
| Total Debt/Equity (mrq) | 11.79 EUR |
| Current Ratio (mrq) | 4.206 |
| Book Value Per Share (mrq) | 2.635 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -355520992 EUR |
| Levered Free Cash Flow (ttm) | -206977872 EUR |
Profile of Iovance Biotherapeutics, Inc.
| Country | Germany |
| State | CA |
| City | San Carlos |
| Address | 825 Industrial Road |
| ZIP | 94070 |
| Phone | 650 260 7120 |
| Website | https://www.iovance.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 503 |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Q&A For Iovance Biotherapeutics, Inc. Stock
What is a current 2LB.F stock price?
Iovance Biotherapeutics, Inc. 2LB.F stock price today per share is 12.23 EUR.
How to purchase Iovance Biotherapeutics, Inc. stock?
You can buy 2LB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Iovance Biotherapeutics, Inc.?
The stock symbol or ticker of Iovance Biotherapeutics, Inc. is 2LB.F.
Which industry does the Iovance Biotherapeutics, Inc. company belong to?
The Iovance Biotherapeutics, Inc. industry is Biotechnology.
How many shares does Iovance Biotherapeutics, Inc. have in circulation?
The max supply of Iovance Biotherapeutics, Inc. shares is 279.31M.
What is Iovance Biotherapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Iovance Biotherapeutics, Inc. PE Ratio is now.
What was Iovance Biotherapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Iovance Biotherapeutics, Inc. EPS is -1.76 EUR over the trailing 12 months.
Which sector does the Iovance Biotherapeutics, Inc. company belong to?
The Iovance Biotherapeutics, Inc. sector is Healthcare.